

A single-dose study of zavegepant in healthy male volunteers

| | | |
|--|--|--|
| Submission date 23/03/2022 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| | | <input type="checkbox"/> Protocol |
| Registration date 01/04/2022 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan |
| | | <input checked="" type="checkbox"/> Results |
| Last Edited 15/07/2022 | Condition category Nervous System Diseases | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

Zavegepant (also known as BHV-3500) is being developed as a treatment for migraine. The aim of this study is to identify the absorption, distribution, metabolism, and excretion of radiolabeled zavegepant.

Who can participate?

Healthy men aged 30 to 60 years

What does the study involve?

Participants will be screened with blood tests, vital signs, electrocardiogram (ECG), physical examination, and completion of the Sheehan Suicidality Tracking Scale (S-STs) to determine study eligibility. If qualified, participants will return to the clinic to check in the day before dosing is planned. After fasting overnight, on the morning of Day 1, an intravenous (IV) infusion tube will be inserted into the participants' arms and they will be given a single 5 mg dose of the test drug, ¹⁴C-zavegepant solution, by IV over 15 minutes. Participants will stay in the clinic until up to 240 hours after dosing (Day 11). During this time, urine, stool and blood samples will be collected to measure the amount of radioactivity being excreted and the participants will be monitored for any adverse events. Participants will be released as a group when over 90% of the dose of radioactivity administered has been recovered or if less than 1% of the dose administered has been collected in urine and stool within two separate consecutive 24-hour periods.

What are the possible benefits and risks of participating?

There will be no benefit to the participants. The main risks will be the frequent collection of blood samples and exposure to radioactivity from the study drug. Blood sampling is a standard procedure which is unlikely to cause subjects any problems but can sometimes cause discomfort. Collecting a blood sample from a vein may cause pain, swelling, bruising, light headedness, fainting, and very rarely, clot formation, nerve damage and/or infection at the site of the needle stick. [¹⁴C]-zavegepant is the test medicine in this study and is radioactive. The radiation is used to trace where the test medicine (and its breakdown products) is in the participant's body. Participants will be exposed to a small amount of radiation that they wouldn't be exposed to if they didn't participate in the study. The amount of radiation that subjects would be exposed to

from the test medicine is slightly more than two abdominal x-rays, for example, and less than annual background radiation exposure.

Where is the study run from?
Quotient Sciences Limited (UK)

When is the study starting and how long is it expected to run for?
February 2020 to August 2020

Who is funding the study?
Biohaven Pharmaceuticals, Inc. (USA)

Who is the main contact?
Nand Singh
Nand.Singh@quotientsciences.com

Contact information

Type(s)
Principal Investigator

Contact name
Dr Nand Singh

Contact details
Quotient Sciences
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)1159749000
Nand.Singh@quotientsciences.com

Type(s)
Public

Contact name
Dr Nand Singh

Contact details
Quotient Sciences
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)1159749000
Nand.Singh@quotientsciences.com

Type(s)

Scientific

Contact name

Dr Nand Singh

Contact details

Quotient Sciences

Mere Way

Ruddington Fields

Ruddington

Nottingham

United Kingdom

NG11 6JS

+44 (0)1159749000

Nand.Singh@quotientsciences.com

Additional identifiers**EudraCT/CTIS number**

2020-000735-41

IRAS number

279969

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

BHV3500-104, IRAS 279969

Study information**Scientific Title**

BHV3500-104: a single-dose study to assess the mass balance recovery, absorption, metabolism and excretion of [14C]-zavegepant (BHV-3500) in healthy male subjects after intravenous dosing

Acronym

BHV3500-104 Human ADME Study

Study objectives

The objectives of this study are to assess the mass balance recovery after a single 15-minute intravenous (IV) infusion dose of ([14C])-zavegepant, and to provide plasma, urine, and fecal samples for metabolite profiling and structural identification.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 15/05/2020, Health and Social Care Research Ethics Committee A (HSC REC A)
(ORECNI Office, Lissue Industrial Estate, West Rathdown Walk, Moira Road, Lisburn, BT28 2RF,
UK; +44(0)28 95361400; RECA@hscni.net), ref: 20/NI/0055

Study design

Phase I open-label single-center single-period non-randomized study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Other

Study type(s)

Other

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Migraine

Interventions

This Phase I, open-label, single-center, single-period, non-randomized study includes healthy male volunteers. After an overnight fast of 8 hours, volunteers are dosed on the morning of Day 1 with a single 5 mg dose of the test drug, ¹⁴C-zavegepant, through intravenous infusion over 15 minutes and remain resident in the clinic until up to 240 h after dosing (Day 11). It is planned that subjects will be released as a group when all subjects have achieved a mass balance cumulative recovery of >90% or if <1% of the dose administered has been collected in urine and feces within two separate, consecutive 24 h periods. Adverse events (AEs), vital signs, electrocardiogram (ECG), Sheehan Suicidality Tracking Scale (S-STs), and physical examination are also assessed.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Zavegepant; BHV-3500; formerly vazegepant

Primary outcome measure

The rates and routes of elimination of the test medicine from the body, and the ways in which the body processes the test medicine will be assessed by taking whole blood, plasma, urine, and feces for liquid scintillation counting to measure the amount of radioactivity, and to identify breakdown products of the test medicine by liquid chromatography with radio detection and

high-resolution mass spectrometry, between Days 1 and Day 11. Participants' stay may be extended an additional 2 days and they may need to continue collections of urine and faeces for a few days at home after they have left the ward.

Secondary outcome measures

1. The intravenous pharmacokinetics of the test medicine in plasma, feces, and urine after a single dose will be assessed by taking blood samples and urine samples for liquid chromatography with tandem mass spectrometry (LC-MS/MS assay) of the test medicine between Days 1 and Day 11
2. Adverse events (to assess tolerability of the test medicine) will be collected by asking volunteers how they are feeling from the start of the trial until follow up
3. Other safety measures (including vital signs, ECGs and laboratory safety tests) will be assessed by standard phase 1 unit monitoring at screening, from Day-1 to discharge from the ward

Overall study start date

13/02/2020

Completion date

28/08/2020

Eligibility

Key inclusion criteria

1. Must provide written informed consent prior to any study-related procedures
2. Healthy males
3. Age 30 to 60 years of age inclusive at the time of signing informed consent
4. Body mass index (BMI) of 18.0 to 32.0 kg/m² as measured at screening
5. Subject's score on the Sheehan Suicidality Tracking Scale (S-STTS) test must be 0
6. Must be able to understand the requirements of the study, and willing and able to communicate and comply with all study procedures
7. Must have regular bowel movements (i.e. average stool production of ≥ 1 and ≤ 3 stools per day)
8. Must agree to adhere to the contraception requirements

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Sex

Male

Target number of participants

6

Total final enrolment

Key exclusion criteria

1. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1
2. Subjects who are, or are immediate family members of a study site or sponsor employee
3. Subjects who have previously been administered IMP in this study
4. History of any drug or alcohol abuse in the past 2 years
5. Regular alcohol consumption >21 units per week (1 unit = ½ pint beer, or a 25 ml shot of 40% spirit, 1.5 to 2 units = 125 ml glass of wine, depending on type)
6. A confirmed positive alcohol breath test at screening or admission
7. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
8. Current smokers and those who have smoked within the last 12 months and/or current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
9. Subjects with partners who are pregnant or lactating or planning to become pregnant during the study or within 90 days after study drug administration
10. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other therapeutic medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening/pre-dose
12. Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator. Subjects with Gilbert's Syndrome are allowed.
13. Confirmed positive drugs of abuse test result at screening or admission
14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
15. Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <80 mL/min using the Cockcroft-Gault equation
16. History of clinically significant cardiovascular, renal, hepatic, pulmonary, gastrointestinal, hematologic, neoplastic, endocrine, immunological, neurological or psychiatric disease or disorder, as judged by the investigator
17. History of clinically significant illness and surgery within 4 weeks prior to dosing. Subjects vomiting within 24 h pre-dose will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the investigator.
18. Significant history of seizure disorder other than a single childhood febrile seizure (e.g. epilepsy)
19. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
20. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
21. Donation or loss of greater than 400 ml of blood within the previous 3 months
22. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies or dietary supplements (other than up to 4 g of paracetamol per day) in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the investigator.
23. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to the first drug administration.
24. Any of the following laboratory parameters above the upper limit of normal (ULN) values at screening or baseline (Day -1): alkaline phosphatase, aspartate aminotransferase (AST), alanine

aminotransferase (ALT), gamma glutamyl-transpeptidase, direct bilirubin, indirect bilirubin, and total bilirubin. Only abnormal values between up to $1.5 \times \text{ULN}$ may be repeated once for confirmation of a return to normal range.

25. Any of the following abnormalities on 12-lead ECG or blood pressure at screening, confirmed by repeat:

25.1. PR (PR interval) ≥ 220 msec

25.2. QRS (QRS complex) ≥ 120 msec

25.3. QT (QT interval) ≥ 500 msec

25.4. QTcF (Fridericia's corrected QT interval) ≥ 450 msec

25.5. Sitting (for at least 5 min) systolic blood pressure > 140 mmHg

25.6. Sitting (for at least 5 min) diastolic blood pressure > 90 mmHg

26. Any of the following abnormal laboratory test values at screening or baseline (Day -1):

26.1. Haemoglobin < 12.8 g/dl

26.2. Haematocrit $< 37\%$

26.3. Total white blood cell $< 3.0 \times 10^9/\text{l}$

26.4. Platelet count $< 100 \times 10^9/\text{l}$

26.5. Neutrophils $< 1.4 \times 10^9/\text{L}$ and $< 1.0 \times 10^9/\text{l}$ for black/African-American subjects

26.6. Creatine kinase $> 3 \times \text{ULN}$

27. Clinically significant history of depression or suicidal thoughts within the previous 12 months prior to screening

28. Failure to satisfy the investigator of fitness to participate for any other reason

Date of first enrolment

17/07/2020

Date of final enrolment

30/07/2020

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Quotient Sciences, Ltd.

Mere Way

Ruddington Fields

Ruddington

Nottingham

United Kingdom

NG11 6JS

Sponsor information

Organisation

Biohaven Pharmaceuticals (United States)

Sponsor details

215 Church St.

New Haven

United States of America

06492

+1 (0)2034040410

mary.donohue@biohavenpharma.com

Sponsor type

Industry

Website

<https://www.biohavenpharma.com/>

ROR

<https://ror.org/00m2ky193>

Funder(s)**Funder type**

Industry

Funder Name

Biohaven Pharmaceuticals, Inc.

Results and Publications**Publication and dissemination plan**

Planned publication as an abstract at a scientific meeting.

Intention to publish date

31/12/2023

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available. The findings of this Phase I study will be shared with the sponsor, Biohaven Pharmaceuticals, Inc. only. As these findings are confidential due to commercial sensitivity, it is not appropriate to share the results of this study with other researchers at this time.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type

[Abstract results](#)

[HRA research summary](#)

Details

Date created

20/05/2022

Date added

15/07/2022

28/06/2023

Peer reviewed?

No

No

Patient-facing?

No

No